Neurofilament light chain and MRI volume parameters as markers of neurodegeneration in multiple sclerosis

被引:2
|
作者
Filippi, Pavol [1 ]
Vestenicka, Veronika [1 ]
Siarnik, Pavel [1 ]
Sivakova, Monika [1 ]
Copikova-Cudrakova, Daniela [1 ]
Belan, Vit'azoslav [2 ]
Hanes, Jozef [3 ]
Novak, Michal [3 ]
Kollar, Branislav [1 ]
Turcani, Peter [1 ]
机构
[1] Comenius Univ, Fac Med, Dept Neurol 1, Mickiewiczova 13, Bratislava 81369, Slovakia
[2] Dr Magnet Kramare, Bratislava, Slovakia
[3] Slovak Acad Sci, Inst Neuroimmunol, Bratislava, Slovakia
关键词
Multiple Sclerosis; Neurofilament Light Chain; Neurodegeneration; Single-molecule Array (SIMOA (R)); Magnetic Resonance Imaging; MRI Volume Parameters; Icobrain; Biomarker; BRAIN ATROPHY; SERUM NEUROFILAMENT; DISABILITY PROGRESSION; DISEASE-ACTIVITY; MATTER; QUANTIFICATION; RELEVANCE; LESIONS; DAMAGE; MS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Neurofilament light chain (NfL) is considered a major marker of neurodegeneration and disease activity. Higher levels of NfL are associated with worse clinical outcomes and increased brain atrophy. In treated patients with Relapsing-Remitting Multiple Sclerosis (RRMS), we aimed to determine the level of NfL, an association between NfL and demographic, clinical and magnetic resonance imaging (MRI) characteristics as well as brain volume parameters. We wanted to confirm that level of NfL is clinically useful as biomarker of neurodegeneration and disease activity. METHODS: 56 treated RRMS patients were enrolled. Plasmatic levels of NfL (pNfL) were measured by SIMOA (R) technique. Clinical severity of MS was expressed by Expanded Disability Status Scale (EDSS), and volumetric analysis of MRI data was performed using Icobrain software. RESULTS: The mean pNfL level was significantly higher in MS patients than in healthy controls (14.73 +/- 6.38 versus 6.67 +/- 3.9, p<0.001). In patients, we did not find association between pNfL and MRI activity, number of new T2 lesions, and number of enhancing lesions. Levels of pNfL correlated significantly with atrophy of whole brain volume (Wbv), atrophy of grey matter volume (Gmv), and negatively with Wbv. We found significantly positive correlation between pNfL levels and EDSS. CONCLUSION: Study shows association of pNfL with Wbv, presence of brain atrophy and EDSS, and strong correlation of EDSS with multiple MRI volume parameters. We did not confirm association pNfL with disease activity. Our data suggest that pNfL and MRI volume parameters could be considered as biomarkers of neurodegeneration in MS.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 50 条
  • [41] Multidimensional overview of neurofilament light chain contribution to comprehensively understanding multiple sclerosis
    Kolliker Frers, Rodolfo A.
    Otero-Losada, Matilde
    Kobiec, Tamara
    Udovin, Lucas D.
    Aon Bertolino, Maria Laura
    Herrera, Maria, I
    Capani, Francisco
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] Decreased neurofilament light chain levels in estriol-treated multiple sclerosis
    Voskuhl, Rhonda
    Kuhle, Jens
    Siddarth, Prabha
    Itoh, Noriko
    Patel, Kevin
    MacKenzie-Graham, Allan
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2022, 9 (08): : 1316 - 1320
  • [43] Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis
    Edwards, Keith R.
    Garten, Lore
    Button, Judy
    O'Connor, Judy
    Kamath, Vineetha
    Frazier, Carol
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 : 59 - 61
  • [44] Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis
    Gaetani, Lorenzo
    Salvadori, Nicola
    Lisetti, Viviana
    Eusebi, Paolo
    Mancini, Andrea
    Gentili, Lucia
    Borrelli, Angela
    Portaccio, Emilio
    Sarchielli, Paola
    Blennow, Kaj
    Zetterberg, Henrik
    Parnetti, Lucilla
    Calabresi, Paolo
    Di Filippo, Massimiliano
    JOURNAL OF NEUROLOGY, 2019, 266 (09) : 2157 - 2163
  • [45] Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis
    Lorenzo Gaetani
    Nicola Salvadori
    Viviana Lisetti
    Paolo Eusebi
    Andrea Mancini
    Lucia Gentili
    Angela Borrelli
    Emilio Portaccio
    Paola Sarchielli
    Kaj Blennow
    Henrik Zetterberg
    Lucilla Parnetti
    Paolo Calabresi
    Massimiliano Di Filippo
    Journal of Neurology, 2019, 266 : 2157 - 2163
  • [46] Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives
    Jakimovski, Dejan
    Dwyer, Michael G.
    Bergsland, Niels
    Weinstock-Guttman, Bianca
    Zivadinov, Robert
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (04) : 329 - 340
  • [47] The association between serum neurofilament light chain, atrophied lesion volume and brain atrophy with disability progression in multiple sclerosis
    Tavazzi, Eleonora
    Ramanathan, Murali
    Barro, Christian
    Hagemeier, Jesper
    Jakimovski, Dejan
    Bergsland, Niels
    Tomic, Davorka
    Kropshofer, Harald
    Leppert, David
    Michalak, Zuzanna
    Dwyer, Michael
    Benedict, Ralph
    Weinstock-Guttman, Bianca
    Kuhle, Jens
    Zivadinov, Robert
    NEUROLOGY, 2019, 92 (15)
  • [48] Neurofilament Proteins as Body Fluid Biomarkers of Neurodegeneration in Multiple Sclerosis
    Gresle, Melissa M.
    Butzkueven, Helmut
    Shaw, Gerry
    MULTIPLE SCLEROSIS INTERNATIONAL, 2011, 2011
  • [49] Aqueous Humor Neurofilament Light Chain is a Marker of Neurodegeneration in Glaucoma
    Lin, Jonathan B.
    Pitts, Kristen
    Neeson, Cameron
    Hall, Nathan Eli
    Falah, Henisk
    El Helwe, Hani
    Wang, Silas
    Lo, Kristine
    Song, Christian
    Margeta, Milica
    Sola-Del Valle, David
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [50] Neurofilament Light Chain in Aqueous Humor as a Marker of Neurodegeneration in Glaucoma
    Lin, Jonathan B.
    Pitts, Kristen M.
    El Helwe, Hani
    Neeson, Cameron
    Hall, Nathan E.
    Falah, Henisk
    Schultz, Stephanie A.
    Wang, Silas L.
    Lo, Kristine
    Song, Christian
    Margeta, Milica A.
    Sola-Del Valle, David
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 2209 - 2217